Patients with solid malignancies who were enrolled on one of four institutional protocols between June 2003 and January 2013 were eligible candidates for CEUS examinations. The protocols included OPTUS [30 (link)], a safety and efficacy study of Optison (perflutren protein-type A microspheres, GE Healthcare) ultrasound contrast agent in children with solid abdominal and pelvic malignancies, and three therapeutic trials: NB05, a single-arm phase II study of gefitinib and irinotecan in children with high-risk neuroblastoma [32 (link)]; ANGIO1, a phase I study of bevacizumab and sorafenib combined with low-dose cyclophosphamide in patients with refractory solid tumors and leukemia [33 (link)]; and RET05, a protocol for the study and treatment of patients with intraocular retinoblastoma [34 (link)]. All protocols were institutional research board approved and HIPAA compliant, and all subjects or their guardians signed informed consent or assent for CEUS as appropriate. The results of the OPTUS study and the CEUS findings of a subset of ANGIO1 subjects have been previously published [30 (link), 33 (link)].
Protocol detail
CEUS in Pediatric Solid Tumors
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Abdominal
Bevacizumab
Children
Contrast agent
Cyclophosphamide
Examinations
Gefitinib
Guardians
Irinotecan
Leukemia
Malignancies
Microspheres
Neuroblastoma
Optison
Patients
Pelvic malignancies
Perflutren
Protein a
Retinoblastoma
Safety
Sorafenib
Tumors
Ultrasound
Corresponding Organization :
Other organizations : St. Jude Children's Research Hospital
Top 5 similar protocols
Variable analysis
independent variables
- Optison (perflutren protein-type A microspheres, GE Healthcare) ultrasound contrast agent
- Gefitinib and irinotecan
- Bevacizumab and sorafenib combined with low-dose cyclophosphamide
- Safety and efficacy of Optison ultrasound contrast agent in children with solid abdominal and pelvic malignancies
- Response to gefitinib and irinotecan in children with high-risk neuroblastoma
- Response to bevacizumab and sorafenib combined with low-dose cyclophosphamide in patients with refractory solid tumors and leukemia
- Patients with solid malignancies enrolled on one of four institutional protocols between June 2003 and January 2013
- Positive control: Not explicitly mentioned.
- Negative control: Not explicitly mentioned.
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!